KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Short-term Investments (2016 - 2025)

Regeneron Pharmaceuticals has reported Short-term Investments over the past 17 years, most recently at $5.5 billion for Q4 2025.

  • Quarterly results put Short-term Investments at $5.5 billion for Q4 2025, down 15.9% from a year ago — trailing twelve months through Dec 2025 was $5.5 billion (down 15.9% YoY), and the annual figure for FY2025 was $5.5 billion, down 15.9%.
  • Short-term Investments for Q4 2025 was $5.5 billion at Regeneron Pharmaceuticals, down from $5.9 billion in the prior quarter.
  • Over the last five years, Short-term Investments for REGN hit a ceiling of $8.1 billion in Q4 2023 and a floor of $1.8 billion in Q2 2021.
  • Median Short-term Investments over the past 5 years was $5.4 billion (2025), compared with a mean of $5.3 billion.
  • Biggest five-year swings in Short-term Investments: skyrocketed 126.87% in 2022 and later crashed 33.57% in 2025.
  • Regeneron Pharmaceuticals' Short-term Investments stood at $2.8 billion in 2021, then soared by 65.05% to $4.6 billion in 2022, then surged by 75.02% to $8.1 billion in 2023, then fell by 19.6% to $6.5 billion in 2024, then dropped by 15.9% to $5.5 billion in 2025.
  • The last three reported values for Short-term Investments were $5.5 billion (Q4 2025), $5.9 billion (Q3 2025), and $5.5 billion (Q2 2025) per Business Quant data.